Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination

Aim of the work

To determine the benefits of statin use in CHC patients treated with Sofosbuvir/Daclatasvir/Ribavirin through :

Primary Outcome: Assessment of therapeutic SVR12

Seconadry Outcome

• assessment of Chronic hepatitis C(CHC) infection risk on development of metabolic syndrome through assessment of lipid profile , fasting glucose test , HgbA1C and C-reactive protein(CRP).

2- Evaluation of CHC related complications such as fibrosis and cirrhosis

Patients will be followed up for the whole study period and will be subjected to assessment of the following:

• CBC , liver function test , lipid profile and CK every month till the end of therapy.
• HgA1C and CRP at the end of therapy.
• HCV-PCR test 3 months after the end of therapy.
• Fibrosis using (FIB-4) 3 months after the end of therapy.

Inclusion criteria

• Male patients age 18 to 70 years old.
• Easy to treat group: treatment naïve patients with serum HCV RNA positivity by PCR.
• Clinically stable condition outpatients.
• Platelet count ≥ 150,000/mm³.
• INR ≤ 1.2.
• Serum albumin ≥ 3.5 g/dl.
• Total serum bilirubin ≤ 1.2 mg/dl.

Exclusion criteria

• Inadequately controlled diabetes mellitus (HbA1c > 9%) .
• Total serum bilirubin > 3mg/dl.
• HCV-HIV co infection.
• HBV-HCV co infection.
• Any cause for chronic liver disease other than hepatitis C
• Uncontrolled hypothyroidism.
• Hepatocellular carcinoma, except 4 weeks after intervention aiming at cure with no evidence of activity by dynamic imaging (CT or MRI).
• Extra-hepatic malignancy except after two years of disease-free interval.
• Child's C cirrhotic patients.
• Creatinine kinase > 350 u/l